Masthead

nCounter®
Canine IO Panel

Masthead

Helping Your Research

Covering hundreds of genes involved in the immune response of canines to immuno-oncology therapeutics and designed with experts in canine comparative oncology, the nCounter Canine IO Panel is the only gene expression panel built to study the tumor and immune response to IO treatments in dogs. The panel takes advantage of tumor-specific coverage for the most common canine cancers to enable researchers to share data and access enhanced statistical power, potentially improving clinical trial success by translating findings from the treatment of spontaneous canine cancer to humans.

Product Highlights:

  • Profile 800 genes across 47 annotated pathways involved in canine immune response to IO treatments
  • Overlapping content with NanoString’s Human PanCancer IO 360 and PanCancer Immune Profiling Panels provides a suite of panels for comparative studies
  • PanCancer coverage with tumor specific content for top canine cancers including Melanoma, Osteosarcoma, Lymphoma, Urothelial Carcinoma, and Glioblastoma
  • Easy to use nCounter system provides data in 24 hours with less than 30 minutes hands on time and simple data analysis
  • Easy data sharing and collaboration with a common set of genes and a panel standard
Canine panel

How It Works

The Canine IO Panel was created through a collaboration between NanoString and the Canine Consortia, a consortium of researchers from multiple prestigious institutes, including the University of Alabama, the University of California- DavisColorado State University, the University of Minnesota, the University of PennsylvaniaTufts, and Freie Univ. Berlin. The Canine Consortia includes key members of the Cancer Moonshot Consortium, which aims to

  • Promote the development of cancer immunotherapies for several common human cancers — glioma, osteosarcoma, melanoma, and lymphoma
  • Foster a collaborative immunotherapy network for comparative

Tumor Specific Coverage for Top Canine Cancers

Included within the Canine IO Panel content are tumor specific targets for five of the top canine cancers, also common in humans:

01:

Melanoma

02:

Osteosarcoma

03:

Lymphoma

04:

Urothelial Carcinoma

05:

Glioblastoma

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Signatures/ Pathways
Specifications
Catalog Information
Signatures/ Pathways

The nCounter Canine IO Panel enables researchers to explore canine immune response to immune-oncology treatments.

Specifications
Catalog Information

Related Resources

See All Resources
Product Bulletin Canine IO Panel – Product Bulletin
Blog NanoString Proudly Introduces the new nCounter® Canine IO Panel.
Virtual Seminar A Tail of Two Species: Oncology Studies with the nCounter Canine IO Panel

Spatially resolved transcriptomics and its applications in cancer

Spatially resolved transcriptomics (SRT) offers the promise of understanding cells and their modes of dysfunction in the context of intact tissues. Technologies for SRT have advanced rapidly with a large number being published in recent years.

NUPR1 is a critical repressor of ferroptosis.

Ferroptosis is a type of iron-dependent regulated cell death, representing an emerging disease-modulatory mechanism. Transcription factors play multiple roles in ferroptosis, although the key regulator for ferroptosis in iron metabolism remains elusive.

Predictive Value of Circulating miRNAs in Lymph Node Metastasis for Colon Cancer.

(1) Background: Lymph node (LN) status is an indubitable prognostic factor for survival among colon cancer patients. MicroRNAs (miRNAs) have been implicated in the development and progression of many cancers and are potential biomarkers for cancer diagnosis and prognosis.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us